Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12971547 | 0.84 | CYP2D6 (0.50) | CYP2D6CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4428909 | 0.78 | CYP2D6 (0.35) | CYP2D6CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL7389442 | 0.75 | DRD4 (0.52) | CYP2D6CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4726 | 0.74 | SIGMAR1 (0.68) | MEN1KMT2APOLBSIGMAR1LMNA | |
| Acetic Acid SCHEMBL27896934 | 0.73 | SIGMAR1 (0.57) | CYP2D6ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6969295 | 0.73 | DRD2 (0.48) | CYP2D6CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL6096440 | 0.73 | MMP13 (0.49) | SMN1; SMN2CHRM2MMP1MMP9MMP13 | |
| SCHEMBL6095559 | 0.73 | MMP13 (0.56) | MMP1MMP9MMP13ADAM17ADAMTS4 | |
| Iodide SCHEMBL1697595 | 0.73 | SIGMAR1 (0.65) | MEN1KMT2APOLBSIGMAR1LMNA | |
| Hydrochloric Acid SCHEMBL5671727 | 0.73 | SIGMAR1 (0.65) | MEN1KMT2APOLBSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1829510-A | Dispersible formulation of an anti-inflammatory agent | PHARMACIA & UPJOHN CO LTD (US) | 2006-09-06 | — | — | CN | claimed |
| EP-1656159-A2 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | Pharmacia & Upjohn Company LLC (US) | 2006-05-17 | — | — | EP | claimed |
| EP-1651210-A1 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | Pharmacia & Upjohn Company LLC (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009472-A2 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009436-A1 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-02-03 | — | — | WO | claimed |
| US-20050009931-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | BRITTEN NANCY JEAN (US) | 2005-01-13 | — | — | US | claimed |
| US-20050004098-A1 | Dispersible formulation of an anti-inflammatory agent | BRITTEN NANCY JEAN (US) | 2005-01-06 | — | — | US | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2006078941-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-1656159-A2 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | Pharmacia & Upjohn Company LLC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1651210-A1 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | Pharmacia & Upjohn Company LLC (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009472-A2 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009436-A1 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050009931-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | BRITTEN NANCY JEAN (US) | 2005-01-13 | — | — | US | disclosed |
| US-20050004098-A1 | Dispersible formulation of an anti-inflammatory agent | BRITTEN NANCY JEAN (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004098-A1 | Dispersible formulation of an anti-inflammatory agent | TNF, IL6, IL1A | CYP2D6 1022/4885CYP3A4 2906/4885CYP2C9 2711/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | CYP2D6 1278/4885CYP3A4 1343/4885CYP2C9 688/4885 |
| US-20170204131-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | NNT, HADHB, NAMPT | CYP2D6 2667/4885CYP3A4 2808/4885CYP2C9 2357/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | CYP2D6 2667/4885CYP3A4 2808/4885CYP2C9 2357/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | CYP2D6 1278/4885CYP3A4 1343/4885CYP2C9 688/4885 |
| US-20050009931-A1 | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | SLC26A4, OTC, ABCB11 | CYP2D6 559/4885CYP3A4 1998/4885CYP2C9 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.